The approval is for adults who have experienced disease progression on or after platinum-based chemotherapy.
Advertisement
Other analyses suggest that lack of ctDNA clearance with neoadjuvant therapy or with MRD postsurgery leads to worse outcomes.
The study examined the effectiveness of various interventions aimed at increasing lung cancer screening uptake rates.
The study investigated HER3-DXd in patients with advanced EGFRm NSCLC after progression during treatment with an EGFR TKI.
Learn more about outcomes from the first minimal residual disease analysis of the DART trial.
Dr. Archambault discusses the safety and effectiveness of cemiplimab plus chemotherapy for first-line treatment of aNSCLC.
Dr. Conkling shared his research insights on PD-L1 testing practices for mNSCLC within US community oncology settings.
The forum covered critical updates in the fields of NSCLC, SCLC, immunotherapy effectiveness, and recent trial updates.
The panel discussed advancements in the field, including results from a study of lurbinectedin plus atezolizumab for SCLC.
Dr. Osarogiagbon shared insights on findings from the incidental lung nodule program and lung cancer screening program.
Amivantamab plus lazertinib showed a statistically significant improvement in OS compared with osimertinib.
Advertisement
Editorial Board
Mara B. Antonoff, MDEditor | Associate Professor, the University of Texas MD Anderson Cancer Center
Stephen V. Liu, MDEditor | Associate Professor, Georgetown University
Coral Olazagasti, MDEditor | Assistant Professor, Sylvester Comprehensive Cancer Center, University of Miami
Eric Singhi, MDEditor | Assistant Professor, the University of Texas MD Anderson Cancer Center
Advertisement
Roundtable Discussions
Expert Interviews
Conference Coverage
Find key news and updates from the European Lung Cancer Congress 2025.
Find lung cancer news and updates from AACR 2025.
Find key news in thoracic oncology from the 61st Annual Meeting of the Society of Thoracic Surgeons.
Find the latest news and updates on lung cancer from the ESMO Congress 2024.
Find the latest updates on lung cancer treatment and research from the IASLC 2024 World Conference on Lung Cancer.
Find the latest updates on lung cancer treatment and research from the 2024 ASCO Annual Meeting.
Our editors detail the latest data and innovations in the lung cancer space presented at ATS 2024.
Our editors provide coverage on the development of innovative cancer therapeutics, as presented at ESMO TAT 2024.
Our editors deliver in-depth coverage of NACLC 2023, a premier event offering the latest data on lung cancer advancements.
Our editors provide comprehensive coverage of ESMO Congress 2023, with a focus on lung cancer.
Our editors detail the latest data and innovations in the lung cancer space, as presented at WCLC 2023.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.